только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 11 / 21
Страница 1 / 27

Список литературы

1. Schapira A.H., Jenner J. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011; №26(6):1049-55.

2. Blauwendraat C., Nalls M.A., Singleton A.B. The genetic architecture of Parkinson's disease. Lancet Neurology 2020; №19(2):170-178.

3. Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2012; №83 (4): 430–436.

4. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol .Neurosurg. Psychiatry 1988; № 51 (6): 745-752.

5. Höllerhage M. Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. Neurobiol 2019; №149:377-418.

6. Левин О.С. Сосудистый паркинсонизм: 20 лет спустя. РМЖ 2017; №21: с.1500-1506.

7. Terashi H., Taguchi T., Aizawa H. Secondary parkinsonism. Nihon Rinsho 2017; №75 (1): 63-70.

8. Coon E.A., Singer W. Synucleinopathies. Continuum 2020; №26(1):72-92.

9. Kovacs G.G. Tauopathies. Clin Neurol 2017; №145: 355-368.

10. McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; №89: c. 1–13.

11. Lang A.E. Corticobasal degeneration: selected developments. Mov Disord 2003; №18 (6): 51-56.

12. Twelves D., Perkins K.S., Counsell С. Systematic review of incidence studies of Parkinson's disease. MovDisord 2003; №18 (1): 19-31.

13. Factor S. A., Weiner W.J. Parkinson's Disease. Diagnosis and Clinical Management. 2008; 819.

14. Van Den Eeden S.K., Tanner C.M., Bernstein A.L. et al. lncidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; №157: 1015- 1022.

15. Benito–León J., Bermejo-Pareja F., Morales-Gonzalez J.M. et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004; 734-741.

16. Baldereschi M., Di Carlo A., Vanni P., et al. Italian Longitudinal Study on Aging Working Group. Lifestyle-related risk factors for Parkinson's disease: a population-based study . Ada Neurol Scand 2003; №108: 10: 239-244.

17. Wirdefeldt K., Adami H.O., Cole P., et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; №26(1): 1-58.

18. Hirtz D., Thurman D.J., Gwinn-Hardy K., et al. How common are the "common" neurologic disorders? Neurology 2007; № 68: 326-337.

19. Гашилова Ф.Ф. Клинические и параклинические аспекты паркинсонизма в Томске. Автореферат дис... канд. мед. наук. Новосибирск, 2006.

20. Докадина Л.В. Паркинсонизм: Клинико-эпидемиологические аспекты и состояние амбулаторной помощи на регионарном уровне. Автореферат дис... канд. мед. наук. М, 2004.

21. Саютина С.Б., Валиулин М.А., Блохина И.А. Распространённость, диагностика и лечение болезни Паркинсона в Иркутской области. Руководство для врачей по материалам 1 Национального конгресса. М, 2008; 280 с.

22. Страчунская Е.Я. Паркинсонизм с позиции современных информационных концепций медицины. Смоленск, 2008; 208 с.

23. Campenhausen S., Bornschein B. Prevalence and incidence of Parkinson's disease in Europe. European Neuropsychopharmacology 2005; №15: 473-490.

24. Pringsheim T., Jette N., Frolkis A. et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; №29(13):1583-1590.

25. Savica R., Grossardt B.R., Bower J. et al. Incidence and Time Trends of Drug- Induced Parkinsonism: A 30-Year Population-Based Study. Movement Disorders, 2017; №2: 227-234.

26. Jellinger K.A. Vascular parkinsonism. Therapy 2008; № 5(2): 237–255.

27. Van Zagten M., Lodder J., Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov disord 1998; №13: 89– 95.

28. Левин О.С. Экстрапирамидные синдромы при цереброваскулярных заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.

29. Lo R.Y. Epidemiology of atypical parkinsonian syndromes. Tzu Chi Medical Journal 2021; 1-13.

30. Fleury V., Brindel P., Nicastro N. et al. Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism Relat Disord 2018; № 54:30-39.

31. Golbe L.I., Davis P.H., Schoenberg B.S. et al. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; №38 (7):1031-1034.

32. Jankovic J. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 2008; №79(4): 368–376.

33. Kim H., Mason S., Foltynie T. et al. Motor complications in Parkinson’s disease: 13‐ year follow‐up of the CamPaIGN cohort. Movement Disorders 2020; №35 (1): 185-190.

34. Van Gilst M. M., Bloem B. R., Overeem S. “Sleep benefit” in Parkinson’s disease: A systematic review. Parkinsonism & Related Disorders 2013; №19(7): 654–659.

35. Leentjens A.F.G., Dujardin K., Marsh L. et al. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism & Related Disorders 2012; №18(10):1084-1088.

36. Bronnick K., Ehrt U., Emre M., et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. Neurol Neurosurg Psychiatry, 2006; №77 (10):1136-1142.

37. Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; №24(15): 2175-2186.

38. Williams-Gray C. H., Foltynie T., Brayne C.E. et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; №130 (7):1787-1798.

39. Ferman T.J., Smith G.E., Boeve B.F. et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. The Clinical Neuropsychologist 2006; № 20(4): 623–636.